EMA Authorised: Omnitrope (somatropin) — Sandoz GmbH

View source ↗

Summary

The European Medicines Agency authorised Omnitrope (somatropin) by Sandoz GmbH for the treatment of Turner syndrome, Prader-Willi syndrome, and pituitary dwarfi…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pituitary Dwarfism
• Prader-willi Syndrome
• Turner Syndrome

Drugs mentioned

• OMNITROPE (somatropin)

Snippet

Status: Authorised. Therapeutic area: Turner Syndrome;Prader-Willi Syndrome;Dwarfism, Pituitary. MAH: Sandoz GmbH. Decision date: 05/08/2025